Bristol-Myers Q2 Earnings Review: Solid Quarter, But Incoming CMO Must Fix Pipeline

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Bristol-Myers Squibb Company (NYSE: BMY ) reported its Q2 2025 earnings yesterday. The Princeton, New Jersey-based Pharma giant exceeded the Street's expectations , reporting $12.3bn of revenues, a figure that was ...